Zai Lab Ltd (HK:9688) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Zai Lab Limited reported a 47% year-on-year increase in net product revenue for the third quarter of 2024, reaching $101.8 million, driven by the successful launch of VYVGART in China. The company continues to advance its pipeline with promising developments, including a positive China study for KarXT in schizophrenia and encouraging global Phase 1 data for ZL-1310 in small cell lung cancer. With a strong cash position and multiple product launches expected, Zai Lab is poised for future growth.
For further insights into HK:9688 stock, check out TipRanks’ Stock Analysis page.